(NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults ...

DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...

DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...

According to Diabète Québec, type 2 diabetes is the most common form, affecting nearly 90% of those living with diabetes, and many eventually require insulin when lifestyle changes and oral ...

Lugano Diamonds & Jewelry Inc. ("Lugano" or the "Company"), a designer, manufacturer, and retailer of high-end jewelry, today announced that the Company and certain of its affiliates have voluntarily ...

A new store design, though, will be found at Winnipeg’s newest London Drugs location, opening on Nov. 21 in CF Polo Park. The ...

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.

Clearlake Capital Group, L.P. ("Clearlake" or the "Firm"), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, ...

Increased regulatory risks from a widening web of privacy obligations and tightening budgets have made using AI to automate ...

Looking at Gracie Nye you'd have no idea she was diagnosed with a killer disease when she was just one years old. The now ...

In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...